

















Forward-looking and cautionary statements



This Presentation on behalf of KP Tissue Inc. (the "Corporation" or "KPT") does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever.

The information contained in this Presentation does not purport to be all-inclusive. This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of securities law.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of the directors, officers or employees of any such entities as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each person receiving this Presentation should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.


Certain statements in this presentation about KPT's and KPLP's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, items such as: the potential construction of the TAD Sherbrooke paper machine, the timing of commencement of construction of TAD Sherbrooke, the timing of commencement of production of TAD Sherbrooke, the anticipated capacity of TAD Sherbrooke, the benefits of TAD Sherbrooke, the cost of TAD Sherbrooke and the anticipated financing structure and timing and cost of financing for TAD Sherbrooke, and KPLP's future business strategy. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking statements are based on certain key expectations and assumptions made by KPT or KPLP, including expectations and assumptions concerning: the on-time and on-budget construction of TAD Sherbrooke; the impact of the TAD Sherbrooke Project on Adjusted EBITDA; the expectation of continued growth in sales of TAD products in the U.S.; improved performance of the Away-From-Home business; and expanded distribution of White Cloud to select U.S. retailers. Although KPT and KPLP believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that such expectations and assumptions will prove to be correct.

Unless otherwise stated, references in this presentation to market shares or KPT's market leadership are based on Nielsen dollar market share data and management estimates.

The following presentation is to review Kruger Products L.P. Q2 2019 financial results

Corporate Structure





Kruger Products Overview





Canada's Leading
Tissue Company



Strong Customer Relationships



Broad Manufacturing Infrastructure



Solid Cash Flow Generation



Prudent Growth Strategy



Experienced Management Team

Q2 2019 Highlights



\$365.7 M

Revenue



7.9%* over 2018

Primarily due to the favourable impact of the Consumer Canada price increase implemented in Q4 2018, price increases in the AFH segment and the benefit of F/X



+14.0% u.s.

\$31.5 M

Adjusted EBITDA¹



2.9% over 2018

- Positive impact of the Consumer Canada and AFH price increases
- Partially offset by unfavourable sales mix and higher cost of sales and SG&A costs
- Pulp costs were neutral YoY

\$0.9 M

Net Income



\$0.7 M over 2018

 Net income of \$0.9 million compared to \$1.6 million a year ago, a decrease of \$0.7 million.

^{*} Includes 26.7% increase in revenues for Mexico to \$25.4 million, which is a low contribution business.

¹ Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure. Q2 of Fiscal 2018 has been restated to reflect IFRS 16 Lease accounting. Refer to the Appendix and MD&A for more information.


Pulp Input Prices




Q2 2019 NBSK prices rose while BEK prices decreased year-over-year in CAD, and both market pulp prices decreased sequentially (NBSK -5.8% and BEK -5.8% in CAD) compared to Q1 2019.

Pulp prices in USD have moderated in Q2 2019 and based on industry forecasts, are expected to remain in a similar range in 2019. The volatile CAD will create further fluctuations in pulp input costs.

NBSK North American List Prices per MT (Q2 2019 +2% YOY in CAD)



BEK List Prices per MT (Q2 2019 -7% YOY in CAD)





Project progressing on time and on budget

All construction permits are secured

• The foundations of the warehouse-converting and paper machine buildings are progressing as per schedule

New mill leadership team in place

 Purchased or contracted most of the assets required for the Project

 Strong interest from existing and new North American customers



OpEx

Good early progress leading to sustainable benefits

 Now entering 6th month of Operational Excellence ("OpEx") project. The program is progressing very well relative to the timeline and goals

 Initial focus was on two core facilities as well as AFH facilities considering results in prior quarters

 Project focused on line efficiencies including capacity, productivity and waste reduction

 Key to support OpEx by building organizational capability and culture to drive program evolution and sustainability

 Also implementing a logistics project with another partner to drive down freight and warehousing costs

 Combined savings target of \$15 to \$20 million on a run-rate basis, by the end of 2020



AFH SEGMENT

Turnaround starting to take hold

 After a weak Q1, Q2 Adjusted EBITDA improvement of \$3.6 million over Q1

OpEx program started to benefit AFH facilities and better customer pricing

New price increase in Canada and the U.S. effective May 1st,
 2019. However, market remains very price competitive

 Improvements are expected in second half of 2019 considering customer pricing, growing traction of OpEx initiatives and more stable input costs



TRADEMARK

Long-term process to reinforce leadership position

- Committed to enhancing leadership position in Canada
- Private label continues to make gains in bathroom tissue category in particular
- More investment in marketing programs and initiatives such as multi-year partnership with NHL, Made in Canada and **Tear Open to Win!**
- Innovation to be launched in back half of the year
- Strengthening customer support
- Maintain significant lead in bathroom and facial tissue categories, solid second position in paper towel



AN ALL-STAR

Our exceptional team of premium Canadian-made products is now an official partner of the NHL®








Purchase specially marked products and look inside for a





PRIVACY POLICY | RULES & REGULATIONS | FAOS






	Bathroom Tissue	Facial Tissue	Paper Towel
Kruger Products	#1 33.7 %	#1 31.6 %	#2 22.0 %
IRVING	19.3%	19.0%	12.0%
P&G	10.5%	0.8%	32.9%
(3) Kimberly-Clark	1.6%	17.9%	0.8%

Source: Nielsen; dollar market share for the 52-week period ended June 15, 2019.









Quarterly Financial Summary

				% Change	
(Million CAD\$, unless otherwise noted)	Q2 2019	Q1 2019	Q2 2018 Restated	Y/Y	Q/Q
Revenue	365.7	351.0	338.8	7.9%	4.2%
Cost of Sales	325.8	320.1	303.6		
Gross Profit	39.9	30.9	35.2	13.6%	29.4%
Gross Margin	10.9%	8.8%	10.4%		
Adjusted EBITDA ¹	31.5	23.6	30.6	2.9%	33.4%
Adjusted EBITDA Margin ¹	8.6%	6.7%	9.0%		
Net Income (Loss)	0.9	(3.2)	1.6		
Net Income (Loss) Margin	0.3%	(0.9)%	0.5%		

¹ Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure. Q2 of Fiscal 2018 have been restated to reflect IFRS 16 Lease accounting.



Quarterly Segmented Results

				% Change	
(Million CAD\$, unless otherwise noted)	Q2 2019	Q1 2019	Q2 2018 Restated	Y/Y	Q/Q
Segmented Revenue ¹					
Consumer	299.7	296.2	279.2	7.3%	1.2%
AFH	66.0	54.8	59.6	10.8%	20.5%
Total Segment Revenue	365.7	351.0	338.8	7.9%	4.2%
Segment Adjusted EBITDA ²					
Consumer	35.4	30.1	34.3		
AFH	(3.0)	(6.6)	(2.4)		
Other	(0.9)	0.1	(1.3)		
Total Segment Adjusted EBITDA ²	31.5	23.6	30.6	2.9%	33.4%
Segment Adjusted EBITDA Margin ²					
Consumer	11.8%	10.2%	12.3%		
AFH	(4.6)%	(12.0)%	(4.0)%		
Total Segment Adjusted EBITDA Margin ²	8.6%	6.7%	9.0%		

¹ The Other segment previously included revenue and profit (loss) associated with the sales of parent rolls and recycled fibre. Any profit (loss) is now included in Consumer or AFH segments as appropriate. The Other segment currently includes certain corporate costs and timing adjustments for certain manufacturing costs included in inventory.

² Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure. Q1 and Q4 of Fiscal 2018 have been restated to reflect IFRS 16 Lease accounting.

Q2 2019 Revenue Compared to Q2 2018



\$26.9 M

Q2 Revenue increase




7.9%* over Q2 2018

Impacted due to a combination of:

- Consumer selling price increase implemented in Canada in Q4 2018
- Price increases in the AFH segment
- Favourable impact of F/X fluctuation on U.S. sales (USD average 1.34 in Q2 2019 compared to 1.29 in Q2 2018)



Geographic revenue segmentation



^{*} Includes \$5.4 M or 26.7% increase in revenues for Mexico, which is a low contribution business.





\$0.9 M

Q2 Adjusted EBITDA¹ increase





Primarily due to the following factors:

- Positive impact of the Consumer Canada and AFH price increases
- Operational transformation initiatives
- Partially offset by:
 - Unfavourable FX
 - Unfavourable sales mix
 - Outsourced manufacturing costs
 - AFH production inefficiencies
 - Increased SG&A costs
- Pulp costs were neutral

¹ Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure. Q2 of Fiscal 2018 has been restated to reflect IFRS 16 Lease accounting.

Q2 2019 Revenue Compared to Q1 2019



\$14.7 M


Q2 Revenue increase




4.2%* over Q1 2019

Primarily due to the following factors:

- Consumer segment was up \$3.5 million or 1.2%
- AFH segment revenue increased by \$11.2 million or 20.5%
- Q2 typically has seasonally higher sales volume than Q1



Geographic revenue segmentation



^{*} Includes \$0.6 M or 2.3% decrease in revenues for Mexico, which is a low contribution business.






\$7.9 MQ2 Adjusted EBITDA¹ increase

33.5% over Q1 2019

Gross Margin



Due to the following factors:

- Higher sales volume typical of Q2 due to normal seasonality
- AFH price increases
- Pulp costs moderated in Q2 versus Q1
- OpEx program cost improvements

¹ Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure. Q2 and Q1 of Fiscal 2018 have been restated to reflect IFRS 16 Lease accounting.





(Million CAD\$, unless otherwise noted)	Q2 2019	Q1 2019
Cash	115.4	135.0
Current Portion of Long-term Debt	9.3	13.8
Long-term Debt*	596.7	590.8
Net Debt	490.5	469.6
LTM Adjusted EBITDA ¹	112.2	111.2
Net Debt/LTM Adjusted EBITDA ¹	4.4	4.2


^{*} Long-term debt includes the TAD Sherbrooke Project financing related to the IQ debenture and Nordea 2 loan. Cash includes the proceeds from this financing net of spending to the end of Q1 on the TAD Sherbrooke Project, a cash balance of \$119.5 million.

¹ Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure.

CAPEX



CAPEX, excluding TAD Sherbrooke Project



- YTD 2019 CAPEX totalled \$57.3 million, including \$43.7 million related to the TAD Sherbrooke Project
- 2019 CAPEX, excluding TAD Sherbrooke, estimated at between \$20 and \$30 million
- 2019 TAD Sherbrooke CAPEX estimated at between \$220 and \$230 million

Conclusion



More favourable factors in 2H of 2019 considering decreasing pressure from input costs, benefits of OpEx and improved customer pricing

- Continue to drive top line growth in all segments
- Committed to defend our leadership position in Canada
- Pricing all of our businesses to offset input costs and restore profitability
- Creating a more efficient and capable supply chain network. In the process of optimizing paper sourcing across the network
- Taking focused short- and medium-term actions to improve AFH performance
- Building ultra-premium capacity with our TAD Sherbrooke project
- Investing to further strengthen our brands
- Building our organizational capability and culture to drive growth for the future